<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37388724</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Incidence and risk factors of tuberculosis in systemic lupus erythematosus patients: a multi-center prospective cohort study.</ArticleTitle><Pagination><StartPage>1157157</StartPage><MedlinePgn>1157157</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1157157</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1157157</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">Both burdens of tuberculosis (TB) and systemic lupus erythematosus (SLE) in China are ranked as top three in the world. SLE patients are at high risk for TB, but so far, there are no guidelines for TB prevention and management targeting this population in China. This study aims to investigate the incidence of active tuberculosis (ATB) and to explore the risk factors for developing ATB in SLE patients, and to provide evidence for TB prevention and management for SLE patients in China.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A multi-center prospective cohort study was conducted. SLE patients were enrolled from clinics and wards of 13 tertiary hospitals in Eastern, Middle, and Western China from September 2014 to March 2016. Baseline demographic features, TB infection status, clinical information, and laboratory data were collected. ATB development was examined during follow-up visits. Kaplan-Meier method was applied to plot survival curves, and Log-rank test was used to evaluate differences. Cox proportional-hazards model was used to explore the risk factors for ATB development.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">With a median follow-up time of 58 months [interquartile range (IQR): 55-62], 16 out of 1361 SLE patients developed ATB. The 1-year incidence of ATB was 368 [95% confidence interval (CI): 46-691] per 100,000. Over a 5-year period, the cumulative incidence of ATB was 1141 [95% CI: 564-1718] per 100,000, and the incidence density was 245 per 100,000 person-years. Cox regression models were constructed with maximum daily dose of glucocorticoids (GCs) as a continuous variable and a categorical variable, respectively. In model 1, maximum daily dose of GCs (pills per day) [adjusted hazard ratio (aHR)=1.16, 95%CI: 1.04-1.30, p=0.010] and TB infection (aHR=8.52, 95%CI: 3.17-22.92, p&lt;0.001) were independent risk factors for ATB development. In model 2, maximum daily dose of GCs&#x2265;30 mg/d (aHR =4.81, 95%CI: 1.09-22.21, P=0.038) and TB infection (aHR=8.55, 95%CI: 3.18-23.00, p&lt;0.001] were independent risk factors for ATB development.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">SLE patients had a higher incidence of ATB compared to the general population. The risk of developing ATB was even higher with increased daily dose of GCs or in a status of TB infection, in which case TB preventive treatment should be considered.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Zhang, Zou, Jiang, Xie, Liu, Yang, Cao, Li, Sun, Zhang, Zhao, Zeng, Shi and Liu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lifan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology Unit, Peking Union Medical College, International Clinical Epidemiology Network, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Xiaoqing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>4&#xa0;+&#xa0;4 Medical Doctor Program, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Lantian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jianghao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Zhengrong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Qifei</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chunlei</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xiaochuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Fengchun</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Key Laboratory of Rheumatology &amp; Clinical Immunology, Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Laboratory of Rheumatology &amp; Clinical Immunology, Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Key Laboratory of Rheumatology &amp; Clinical Immunology, Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Xiaochun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaoqing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology Unit, Peking Union Medical College, International Clinical Epidemiology Network, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ETHERTB study team</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014376" MajorTopicYN="Y">Tuberculosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055985" MajorTopicYN="Y">Latent Tuberculosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062606" MajorTopicYN="N">Tertiary Care Centers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cohort study</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">risk facors</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">tuberculosis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>30</Day><Hour>13</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>30</Day><Hour>10</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37388724</ArticleId><ArticleId IdType="pmc">PMC10304284</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1157157</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
WHO: global tuberculosis report. Geneva: World Health Organization (2021). Available at: https://www.who.int/teams/global-tuberculosis-programme/data.</Citation></Reference><Reference><Citation>Xiaofeng Z, Mengtao L, Xinping T. National clinical research center for dermatologic and immunologic diseases: systemic lupus erythematosus in China: a national report of 2020. Shenyang: Liaoning Science and Technology Press; (2021).</Citation></Reference><Reference><Citation>Institute of Pathogen Biology. Chinese Academy of Medical Sciences and Peking Union Medical College. Chinese Center for Disease Control and Prevention. Union Medical Institute of Geographic Sciences and Natural Resources Research. Chinese Academy of Sciences . Expert consensus on the estimation of the national burden on latent tuberculosis infection. Chin J Antituberculosis (2022) 44(1):4&#x2013;8. doi: 10.19982/j.issn.1000-6621.20210662</Citation><ArticleIdList><ArticleId IdType="doi">10.19982/j.issn.1000-6621.20210662</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman-Adams H, Clark K, Juckett G. Update on latent tuberculosis infection. Am Fam Physician (2014) 89(11):889&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">25077395</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Di, Deng D. Correlation between systemic lupus erythematosus and tuberculosis. China J Leprosy Skin Dis (2021) 37(8):549&#x2013;52. doi: 10.12144/zgmfskin202108549</Citation><ArticleIdList><ArticleId IdType="doi">10.12144/zgmfskin202108549</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Ma Li. Literature review analysis of systemic lupus erythematosus complicated with tuberculosis infection in China. Chin J Rheumatol (2009) 13(9):599&#x2013;602. doi: 10.3760/cma.j.issn.1007-7480.2009.09.005</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.1007-7480.2009.09.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao X, Da G, Xie X, Liu X, Zhang L, Zhou B, et al. . Tuberculosis in patients with systemic lupus erythematosus-a 37-year longitudinal survey-based study. J Intern Med (2021) 290(1):101&#x2013;15. doi: 10.1111/joim.13218</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13218</ArticleId><ArticleId IdType="pubmed">33259665</ArticleId></ArticleIdList></Reference><Reference><Citation>Lao M, Chen D, Wu X, Chen H, Qiu Q, Yang X, et al. . Active tuberculosis in patients with systemic lupus erythematosus from southern China: a retrospective study. Clin Rheumatol (2019) 38(2):535&#x2013;43. doi: 10.1007/s10067-018-4303-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-018-4303-z</ArticleId><ArticleId IdType="pubmed">30244432</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Liu G, Sun Y. Clinical analysis of 93 cases of systemic lupus erythematosus complicated with tuberculosis. J South Med Univ (2007) 27(5):615&#x2013;7. doi: 10.3321/j.issn:1673-4254.2007.05.035</Citation><ArticleIdList><ArticleId IdType="doi">10.3321/j.issn:1673-4254.2007.05.035</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng CF, Huang YM, Lu CH, Hsieh SC, Li KJ. Prednisolone dose during treatment of tuberculosis might be a risk factor for mortality in patients with systemic lupus erythematosus: a hospital-based cohort study. Lupus (2019) 28(14):1699&#x2013;704. doi: 10.1177/0961203319882759</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319882759</ArticleId><ArticleId IdType="pubmed">31640531</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H. The clinical characteristics of 11 systemic lupus erythematosus patients with central nervous system tuberculosis infection. Chin J Clin (Electronic Edition) (2011) 05(22):6603&#x2013;7. doi: 10.3877/cma.j.issn.1674-0785.2011.22.017</Citation><ArticleIdList><ArticleId IdType="doi">10.3877/cma.j.issn.1674-0785.2011.22.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med (2017) 167(4):248&#x2013;55. doi: 10.7326/M17-0609</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M17-0609</ArticleId><ArticleId IdType="pubmed">28761946</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO . WHO operational handbook on tuberculosis. In: Module 1: prevention - tuberculosis preventive treatment. Geneva: World Health Organization. Available at: https://www.who.int/publications/i/item/9789240002906.</Citation></Reference><Reference><Citation>Park DW, Chung SJ, Yeo Y, Park TS, Lee H, Moon JY, et al. . Therapeutic issues with, and long-term outcomes of, pulmonary mycobacterial tuberculosis treatment in patients with autoimmune rheumatic diseases. J Thorac Dis (2019) 11(11):4573&#x2013;82. doi: 10.21037/jtd.2019.10.74</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jtd.2019.10.74</ArticleId><ArticleId IdType="pmc">PMC6940271</ArticleId><ArticleId IdType="pubmed">31903246</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, Zhang H, Xin H, Liu J, Pan S, Li X, et al. . Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J (2018) 52(6):1801470. doi: 10.1183/13993003.01470-2018</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01470-2018</ArticleId><ArticleId IdType="pubmed">30361241</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun JE, Lee SW, Kim TH, Jun JB, Jung S, Bae SC, et al. . The incidence and clinical characteristics of mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol (2002) 20(2):127&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">12051389</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodkinson B, Musenge E, Tikly M. Osteoarticular tuberculosis in patients with systemic lupus erythematosus. QJM (2009) 102(5):321&#x2013;8. doi: 10.1093/qjmed/hcp015</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcp015</ArticleId><ArticleId IdType="pubmed">19246552</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhammed H, Jain A, Pattanaik SS, Chatterjee R, Naveen R, Kabeer H, et al. . Clinical spectrum of active tuberculosis in patients with systemic lupus erythematosus. Rheumatol Int (2021) 41(12):2185&#x2013;93. doi: 10.1007/s00296-021-04933-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-04933-0</ArticleId><ArticleId IdType="pubmed">34191047</ArticleId></ArticleIdList></Reference><Reference><Citation>Victorio-Navarra ST, Dy EE, Arroyo CG, Torralba TP. Tuberculosis among Filipino patients with systemic lupus erythematosus. Semin Arthritis Rheum (1996) 26(3):628&#x2013;34. doi: 10.1016/s0049-0172(96)80013-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0049-0172(96)80013-8</ArticleId><ArticleId IdType="pubmed">8989807</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamijoyo L, Sahiratmadja E, Ghassani NG, Darmawan G, Susandi E, van Crevel R, et al. . Tuberculosis among patients with systemic lupus erythematosus in Indonesia: a cohort study. Open Forum Infect Dis (2022) 9(7):ofac201. doi: 10.1093/ofid/ofac201</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac201</ArticleId><ArticleId IdType="pmc">PMC9251660</ArticleId><ArticleId IdType="pubmed">35794932</ArticleId></ArticleIdList></Reference><Reference><Citation>Erdozain JG, Ruiz-Irastorza G, Egurbide MV, Martinez-Berriotxoa A, Aguirre C. High risk of tuberculosis in systemic lupus erythematosus? Lupus (2006) 15(4):232&#x2013;5. doi: 10.1191/0961203306lu2289xx</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203306lu2289xx</ArticleId><ArticleId IdType="pubmed">16686263</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam LS, Li EK, Wong SM, Szeto CC. Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol (2002) 31(5):296&#x2013;300. doi: 10.1080/030097402760375205</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/030097402760375205</ArticleId><ArticleId IdType="pubmed">12455821</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Zhang L, Zhang F, Zeng X, Zhao Y, Wang Q, et al. . Prevalence and risk factors of active tuberculosis in patients with rheumatic diseases: a multi-center, cross-sectional study in China. Emerg Microbes Infect (2021) 10(1):2303&#x2013;12. doi: 10.1080/22221751.2021.2004864</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2004864</ArticleId><ArticleId IdType="pmc">PMC8654396</ArticleId><ArticleId IdType="pubmed">34753408</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1997) 40(9):1725. doi: 10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Uribe AG, Vila LM, McGwin G, Jr., Sanchez ML, Reveille JD, Alarcon GS. The systemic lupus activity measure-revised, the Mexican systemic lupus erythematosus disease activity index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol (2004) 31(10):1934&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">15468356</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou ZR, Wang WW, Li Y, Jin KR, Wang XY, Wang ZW, et al. . In-depth mining of clinical data: the construction of clinical prediction model with r. Ann Transl Med (2019) 7(23):796. doi: 10.21037/atm.2019.08.63</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2019.08.63</ArticleId><ArticleId IdType="pmc">PMC6989986</ArticleId><ArticleId IdType="pubmed">32042812</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO . Tuberculosis profile: China. World Health Organization. Available at: https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&amp;entity_type=%22country%22&amp;lan=%22EN%22&amp;iso2=%22CN%22.</Citation></Reference><Reference><Citation>Gupta L, Aggarwal R, Naveen R, Lawrence A, Zanwar A, Misra DP, et al. . High prevalence of active tuberculosis in adults and children with idiopathic inflammatory myositis as compared with systemic lupus erythematosus in a tuberculosis endemic country: retrospective data review from a tertiary care centre in India. Mediterr J Rheumatol (2021) 32(2):134&#x2013;42. doi: 10.31138/mjr.32.2.134</Citation><ArticleIdList><ArticleId IdType="doi">10.31138/mjr.32.2.134</ArticleId><ArticleId IdType="pmc">PMC8369275</ArticleId><ArticleId IdType="pubmed">34447909</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah M, Dorman SE. Latent tuberculosis infection. N Engl J Med (2021) 385(24):2271&#x2013;80. doi: 10.1056/NEJMcp2108501</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp2108501</ArticleId><ArticleId IdType="pubmed">34879450</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO . WHO consolidated guidelines on tuberculosis: module 1. In: Prevention: tuberculosis preventive treatment. Geneva: World Health Organization;  (2020). Available at: https://www.who.int/publications/i/item/9789240001503.</Citation><ArticleIdList><ArticleId IdType="pubmed">32186832</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy Chowdhury R, Vallania F, Yang Q, Lopez Angel CJ, Darboe F, Penn-Nicholson A, et al. . A multi-cohort study of the immune factors associated with m. tuberculosis infection outcomes. Nat (2018) 560(7720):644&#x2013;8. doi: 10.1038/s41586-018-0439-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0439-x</ArticleId><ArticleId IdType="pmc">PMC6414221</ArticleId><ArticleId IdType="pubmed">30135583</ArticleId></ArticleIdList></Reference><Reference><Citation>Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. . Tuberculosis. Nat Rev Dis Primers (2016) 2:16076. doi: 10.1038/nrdp.2016.76</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.76</ArticleId><ArticleId IdType="pubmed">27784885</ArticleId></ArticleIdList></Reference><Reference><Citation>Prezzemolo T, Guggino G, La Manna MP, Di Liberto D, Dieli F, Caccamo N. Functional signatures of human CD4 and CD8 T cell responses to mycobacterium tuberculosis. Front Immunol (2014) 5:180. doi: 10.3389/fimmu.2014.00180</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00180</ArticleId><ArticleId IdType="pmc">PMC4001014</ArticleId><ArticleId IdType="pubmed">24795723</ArticleId></ArticleIdList></Reference><Reference><Citation>Gideon HP, Phuah J, Myers AJ, Bryson BD, Rodgers MA, Coleman MT, et al. . Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization. PloS Pathog (2015) 11(1):e1004603. doi: 10.1371/journal.ppat.1004603</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004603</ArticleId><ArticleId IdType="pmc">PMC4303275</ArticleId><ArticleId IdType="pubmed">25611466</ArticleId></ArticleIdList></Reference><Reference><Citation>Targeted tuberculin testing and treatment of latent tuberculosis infection. this official statement of the American thoracic society was adopted by the ATS board of directors, July 1999. this is a joint statement of the American thoracic society (ATS) and the centers for disease control and prevention (CDC). this statement was endorsed by the council of the infectious diseases society of america. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med (2000) 161(4 Pt 2):S221&#x2013;247. doi: 10.1164/ajrccm.161.supplement_3.ats600</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.161.supplement_3.ats600</ArticleId><ArticleId IdType="pubmed">10764341</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, Li X, Liu J, Wang X, Lu W, Bai L, et al. . Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis (2017) 17(10):1053&#x2013;61. doi: 10.1016/S1473-3099(17)30402-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(17)30402-4</ArticleId><ArticleId IdType="pubmed">28716677</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xie J, Meijer AH, Schaaf MJM. Glucocorticoid-induced exacerbation of mycobacterial infection is associated with a reduced phagocytic capacity of macrophages. Front Immunol (2021) 12:618569. doi: 10.3389/fimmu.2021.618569</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.618569</ArticleId><ArticleId IdType="pmc">PMC8148013</ArticleId><ArticleId IdType="pubmed">34046029</ArticleId></ArticleIdList></Reference><Reference><Citation>Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol (2017) 17(4):233&#x2013;47. doi: 10.1038/nri.2017.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.1</ArticleId><ArticleId IdType="pmc">PMC9761406</ArticleId><ArticleId IdType="pubmed">28192415</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Gonzalez P, Romero-Diaz J, Cervera-Hernandez ME, Ocampo-Torres M, Chaires-Garza LG, Lastiri-Gonzalez EA, et al. . Tuberculosis and systemic lupus erythematosus: a case-control study in Mexico city. Clin Rheumatol (2018) 37(8):2095&#x2013;102. doi: 10.1007/s10067-018-4109-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-018-4109-z</ArticleId><ArticleId IdType="pubmed">29675624</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Naranjo LA, Coral-Enriquez JA, Restrepo-Escobar M, Munoz-Vahos CH, Jaramillo-Arroyave D, Vanegas-Garcia AL, et al. . Factors associated with active tuberculosis in Colombian patients with systemic lupus erythematosus: a case-control study. Clin Rheumatol (2021) 40(1):181&#x2013;91. doi: 10.1007/s10067-020-05225-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05225-x</ArticleId><ArticleId IdType="pubmed">32529420</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantini F, Niccoli L, Capone A, Petrone L, Goletti D. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf (2019) 18(5):415&#x2013;25. doi: 10.1080/14740338.2019.1612872</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2019.1612872</ArticleId><ArticleId IdType="pubmed">31066297</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Gonzalez P, Romero-Diaz J, Cervera-Hernandez ME, Ocampo-Torres M, Chaires-Garza LG, Lastiri-Gonzalez EA, et al. . Tuberculosis and systemic lupus erythematosus: a case-control study in Mexico City. Clin Rheumatol (2018) 37(7):2095&#x2013;2102.</Citation><ArticleIdList><ArticleId IdType="pubmed">29675624</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>